Mozambique is affected by circulating vaccine-derived poliovirus
Circulation of vaccine-derived poliovirus type 2 (cVDPV2) has been confirmed in Mozambique.
The detection of cVDPV2 underscores the importance of maintaining high routine vaccination coverage everywhere to minimize the risk and consequences of any poliovirus circulation. A robust outbreak response is needed to rapidly stop circulation and ensure sufficient vaccination coverage in the affected areas to prevent similar outbreaks in the future. WHO will continue to evaluate the epidemiological situation and outbreak response measures being implemented.
Polio this week in Mozambique
- A new circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreak has been confirmed in Mozambique.
- Two genetically-linked circulating vaccine-derived poliovirus type 2 (cVDPV2) isolates were detected, from an acute flaccid paralysis (AFP) case (with onset of paralysis on 21 October 2018, in a six-year old girl with no history of vaccination, from Molumbo district, Zambézia province), and a community contact of the case.
- The GPEI and partners are working with country counterparts to support the local public health authorities in conducting a field investigation (clinical, epidemiological and immunological) and thorough risk assessment to discuss planning and implementation of immunization and outbreak response.
- In January 2017, a single VDPV2 virus had been isolated from a 5-year old boy with AFP, also from Zambézia province (Mopeia district). Outbreak response was conducted in the first half of 2017 with monovalent oral polio vaccine type 2 (mOPV2).
- Learn more about vaccine-derived polioviruses through this short animation or this ‘Coffee with Polio Experts’ video.
International Health Regulations
Countries affected by poliovirus transmission are subject to International Health Regulations Temporary Recommendations that request them to declare a case of polio as a national public health emergency and consideration vaccination of all international travellers, as per temporary recommendations issued as of November 2018.
WHO’s International Travel and Health recommends that all travellers to polio-affected areas be fully vaccinated against polio. Residents (and visitors for more than 4 weeks) from infected areas should receive an additional dose of OPV or inactivated polio vaccine (IPV) within 4 weeks to 12 months of travel.